span of the relevant patents and at that point both parties can decide whether to renew the agreement or not. He added that the agreement allows Chemicon to access all of WARF's stem cell patents including those filed after the agreement signing. The deal is the first of a licensing program with new flexible terms which will allow WARF to get its patent listing into the market. Since